Medtronic’s SynchroMed II implantable drug pump device, which has been recalled three times in recent years and tied to 14 deaths, has continued to be problematic for the medtech company. A three-page ...
Mylan has rejected Teva’s unsolicited bid. Robert J. Coury, Mylan’s executive chairman, said Teva’s roughly $40 billion offer grossly undervalues the company and “would require Mylan’s shareholders to ...
CHICAGO (Reuters) - Medtronic Inc has sent a letter to physicians warning about possible reduced battery performance in a small percentage of its SynchroMed II Implantable Drug Infusion Pumps, the ...
No one is looking in the rearview mirror at Medtronic plc as a fresh U.S. FDA approval for the next generation version of its intrathecal drug delivery system allows the company to leave behind a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback